TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03784001

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Gratitude + No Expectations Intervention
Description: Participants will be emailed six different times, once every two days, with a link to an anonymous Google form. Each Google form will instruct participants to type a short gratitude list of up to five items. Additionally, the first form will include a demographics questionnaire and the first and sixth forms will include questionnaires assessing all outcomes of interest

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gratitude + Expectations Intervention
Description: Participants will be emailed six different times, once every two days, with a link to an anonymous Google form. Each Google form will instruct participants to type a short gratitude list of up to five items. Participants will have a statement at the top of their Google form about the benefits of gratitude. Examples of these statements are: Practicing gratitude may increase social connectedness and Cultivating gratitude was shown to improve school satisfaction in a UK sample of students. Additionally, the first form will include a demographics questionnaire and the first and sixth forms will include questionnaires assessing all outcomes of interest

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Events Control Intervention
Description: Participants will be emailed six different times, once every two days, with a link to an anonymous Google form. Each Google form will instruct participants to type a list of up to five items about events from their day. Additionally, the first form will include a demographics questionnaire and the first and sixth forms will include questionnaires assessing all outcomes of interest.
Study: NCT01509144

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: EN41-FPA2 HIV vaccine
Description: Group 1 Nasal vaccine - Low-dose (20 µg in 40 µL) IM vaccine (200 µg in 400 µL)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: EN41-FPA2 HIV vaccine
Description: Group 2 Nasal vaccine - Mid-dose (100 µg in 200 µL) IM vaccine (200 µg in 400 µL)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: EN41-FPA2 HIV vaccine
Description: Group 3 Nasal vaccine - Full-dose (200 µg in 400 µL) IM vaccine (200 µg in 400 µL)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: EN41-FPA2 HIV vaccine
Description: Group 4 Nasal Placebo - 400 µL IM vaccine (200 µg in 400 µL)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Na Cl Placebo vaccine
Description: Group 5 Nasal placebo - 40 µL in Cohort 1 / 200 µL in Cohort 2 IM placebo (400 µL)
Study: NCT03525067

Intervention type: OTHER
Intervention: Bile sampling for bacterial examination
Description: At the beginning of pancreaticoduodenectomy, patients had bile sampling from the gallbladder or from the common bile duct for bacterial examination and study of susceptibility to antibiotics.
Study: NCT01158287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Study: NCT03570489

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Patients will bicycle for 20 minutes per day for 5 days per week for 6 months

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Relaxation
Description: Patients will listen to a relaxation tape 20 minutes per day 5 Days a week for 6 months
Study: NCT03245047

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral Nutritional Supplement with AN 777
Description: Oral Nutritional Supplement with AN 777, 2 servings a day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Oral Nutritional Supplement
Description: Oral Nutritional Supplement, 2 servings a day
Study: NCT01156376

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Potassium Oxalate without Fluoride
Description: 1.40% Potassium Oxalate Sensitive Mouthwash without fluoride - Rinse with 10ml for 60 seconds, four times daily successively at 1 hour intervals for five days

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Potassium Oxalate with Fluoride
Description: 1.40% Potassium Oxalate Sensitive Mouthwash with fluoride - Rinse with 20ml for 60 seconds, four times daily successively at 1 hour intervals for five days

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator PO-116-A
Description: Rinse with comparator mouthwash 20ml for 30 seconds, four times daily successively at 1 hour intervals for five days
Study: NCT01170793

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: educative telephone coaching (ETC)
Description: a 30 to 45 minutes phone call, by appointment, by the nurse
Study: NCT01390662

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: one tablet of vitamin D3 70 µg pr. day, for 24 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: one tablet of sugar pill pr. day, for 24 weeks.
Study: NCT01219907

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HER-2/neu peptide vaccine
Description: Given intradermally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ex vivo-expanded HER2-specific T cells
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunoenzyme technique
Description: Correlative studies
Study: NCT01217853

Intervention type: DEVICE
Intervention: SENSIMED Triggerfish
Description: Contact lens-based device for continuous intraocular pressure monitoring
Study: NCT04427943

Intervention type: PROCEDURE
Intervention: revision surgery
Description: The intervention is the planned revision surgery according to local guidelines.
Study: NCT01506440

Intervention type: PROCEDURE
Intervention: cognitive assessment
Description: Given cognitive assessments

Intervention type: PROCEDURE
Intervention: quality-of-life assessment
Description: Ancillary studies
Study: NCT03894072

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Description: Conventional CPAP

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Description: Conventional CPAP

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HFHO
Description: A device that can provide heated humidified oxygen up to 30-60 liter per minute, FiO2 (fraction of inspired oxygen) 0.21-0.95

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HFHO
Description: A device that can provide heated humidified oxygen up to 30-60 liter per minute, FiO2 (fraction of inspired oxygen) 0.21-0.95
Study: NCT00821951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: 200 mg, 300 mg, 400 mg, once per RT fraction

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Standard fractionation of 3.0 Gy per day over 2 weeks, to a total dose of 30 Gy, will be utilized for all patients. All patients will be treated one time per day, 5 days per week unless interruption is clinically indicated.
Study: NCT03791554

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group A (Lateral closed tunnel subepithelial CT graft)
Description: Subepithelial connective tissue graft (autogenous graft) will be harvested from the palate by Single incision technique to be used with the adjacent teeth to treating gingival recession with edges of the recession sutured together after placing connective tissue graft

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group B (Tunnel procedure with subepithelial CT graft)
Description: Subepithelial connective tissue graft (autogenous graft) will be harvested from the palate by Single incision technique to be used with the prepared tunnel to treating gingival recession
Study: NCT02318953

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile app follow-up care
Description: The mobile app follow-up care is an application that can be loaded on to a smartphone. It allows the patient to submit photos of their surgical site, VAS pain scores, and QoR9 scores. The information collected is transmitted to members of the surgical team (i.e. the primary surgeon) and used to monitor recovery over the first 30-days following surgery.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional, in-person follow-up care
Description: This includes a typical in-person visit with the operating surgeon at one- and four-weeks after surgery.
Study: NCT05082753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin tablets (3 mg Ivermectin)
Description: Two Ivermectin tablets were administered orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivermectin tablets (3 mg Ivermectin)
Description: Two Ivermectin tablets were administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stromectol ® tablets
Description: Two Ivermectin tablets were administered orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stromectol ® tablets
Description: Two Ivermectin tablets were administered orally.
Study: NCT03266926

Intervention type: DRUG
Intervention: Bupivacaine
Description: 0.25% Bupivacaine with epinephrine will be applied to vaginal packing that is placed post vaginal reconstruction surgery.

Intervention type: DRUG
Intervention: Premarin Vaginal cream
Description: A Premarin vaginal cream will be used to coat the vaginal pack, prior to insertion in patients post vaginal reconstruction surgery.
Study: NCT03841318

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood sample
Description: 36 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: biopsy of the labial salivary gland
Description: Part of the biopsy of the labial salivary gland
Study: NCT04419298

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac MRI
Description: 1. Cardiac MRI be taken to acute CO poisoned patients with elevated TnI \[during acute (within 7 days after CO exposure) and chronic phase (at 4-5 months after CO exposure)\]~2. TTE be taken to acute CO poisoned patients with elevated TnI \[At the ED and during admission (within 7 days after CO exposure)\]
Study: NCT01779570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macrolide treatment
Study: NCT03921723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir dispersible tablet
Description: DTG will be available as an oral tablet with dosing strength of 5 mg 2 tablet will be dispersed in water will be administered orally for prescribed regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir oral suspension
Description: DTG will be available as an oral suspension with dosing strength of 5 mg per milliliter (ml) or 2 mg per ml with miglyol 812N or ethyl cellulose in miglyol 812N as vehicle for suspension administered orally for prescribed regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir oral solution
Description: DTG will be available as an oral solution with dosing strength of 2 mg per ml will be administered orally for prescribed regimen.
Study: NCT02797652

Intervention type: PROCEDURE
Intervention: Neoadjuvant chemotherapy before surgery
Description: The operable breast cancer patients takes neoadjuvant chemotherapy before surgery.

Intervention type: PROCEDURE
Intervention: Surgery followed by adjuvant chemotherapy
Description: The operable breast cancer patients takes surgery followed by adjuvant chemotherapy.
Study: NCT01233362

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Modified killed oral cholera vaccine at 14 day interval
Description: The modified killed bivalent (O1 and O139)whole cell based oral cholera vaccine is administered orally in 2 liquid doses (without need of any buffer solution) 14 days for individuals aged 1 year and above.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Modified killed oral cholera vaccine at 14 day interval
Description: The modified killed bivalent (O1 and O139)whole cell based oral cholera vaccine is administered orally in 2 liquid doses (without need of any buffer solution) 14 days for individuals aged 1 year and above.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Modified killed oral cholera vaccine at 14 day interval
Description: The modified killed bivalent (O1 and O139)whole cell based oral cholera vaccine is administered orally in 2 liquid doses (without need of any buffer solution) 14 days for individuals aged 1 year and above.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Modified killed oral cholera vaccine at 28 day interval
Description: The modified killed bivalent (O1 and O139)whole cell based oral cholera vaccine is administered orally in 2 liquid doses (without need of any buffer solution) 28 days for individuals aged 1 year and above; as an alternate schedule.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Modified killed oral cholera vaccine at 28 day interval
Description: The modified killed bivalent (O1 and O139)whole cell based oral cholera vaccine is administered orally in 2 liquid doses (without need of any buffer solution) 28 days for individuals aged 1 year and above; as an alternate schedule.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Modified killed oral cholera vaccine at 28 day interval
Description: The modified killed bivalent (O1 and O139)whole cell based oral cholera vaccine is administered orally in 2 liquid doses (without need of any buffer solution) 28 days for individuals aged 1 year and above; as an alternate schedule.
Study: NCT04007328

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline manufactured to mimic methylprednisolone vial
Study: NCT00183651

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard dialectical behavior therapy (SDBT)
Description: Standard DBT includes: 1) individual DBT therapy (1 hour per week), 2) DBT group skills training (2.5 hours per week), 3) telephone consultation (as needed), and 4) therapist consultation team (1 hour per week).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual DBT with no DBT group sessions (DBT-I)
Description: Individual DBT (DBT-I) is 1 hour per week of individual therapy and 2.5 hours per week with the psychosocial activities group.
Study: NCT04161729

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Magnesium Sulfate
Description: Intravenous magnesium sulfate 20 mg/kg in 100ml isotonic saline 0.9% over a 15-min period before induction of anesthesia and 20 mg/kg/h by continuous i.v. infusion until surgery completion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulfate
Description: Intravenous magnesium sulfate 20 mg/kg in 100ml isotonic saline 0.9% over a 15-min period before induction of anesthesia and 20 mg/kg/h by continuous i.v. infusion until surgery completion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic saline 0.9%
Description: Isotonic saline 0.9% 100ml over a 15-min period before induction of anesthesia and thereafter continuous i.v. infusion until surgery completion in dosage identical to magnesium sulfate group.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isotonic saline 0.9%
Description: Isotonic saline 0.9% 100ml over a 15-min period before induction of anesthesia and thereafter continuous i.v. infusion until surgery completion in dosage identical to magnesium sulfate group.
Study: NCT02954744

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HIFU treatment
Description: High intensity focused ultrasound
Study: NCT04151836

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise education
Description: weekly telephone or mobile application LINE consultations concerning exercise. we discussed whether participants' exercise fulfilled the prescribed intensity, duration, or frequency and whether the participants experienced any adverse effects.
Study: NCT01482689

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish oil capsule (specially manufactured for the study)
Description: One capsule per day for 4 weeks (28 days). The fish oil group receives a daily supplement of one fish oil capsule, specially manufactured for the present study by Peter Möller (now Möller's, Nydalen, Norway). The fish oil capsules are aimed to contain a dose of cholecalciferol identical to the dose already found in the multivitamin tablets by analysis in an independent laboratory (AS Vitas, Oslo, Norway), and similar doses of vitamin A. In addition, the fish oil capsule contains vitamin E and n-3 fatty acids.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multivitamin tablet of type: Vitaplex ABCD
Description: One tablet per day for 4 weeks (28 days). The multivitamin group receives a daily supplement of one multivitamin tablet of type Vitaplex ABCD (Cederroth AS, Revetal, Norway), a common vitamin supplement sold in grocery stores in Norway. In addition to 10 micrograms (400 IU) of cholecalciferol,the multivitamin tablet contains vitamin A and the water-soluble vitamins: B1, B2, B6, Niacin, pantothenic acid, and vitamin C.
Study: NCT01643044

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Nutrition time control/placebo intervention
Description: This time-control intervention, designed in part to help promote research assistant blinding as to participant condition, focused on proper infant nutrition using a computer-delivered, interactive format and videos.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer-delivered, brief intervention on alcohol use
Description: A single 20-minute interactive computer-delivered intervention designed to promote motivation to change prenatal alcohol use, without presuming the participant to be currently using alcohol while pregnant.
Study: NCT01430234

Intervention type: DRUG
Group type: OTHER
Intervention: Panzytrat 25.000 FIP-E units of Lipase
Description: patients will experiment with Panzytrat (containing 25.000 units of lipase) to a maximum of 16 capsules a day according to general guidelines.
Study: NCT00183651

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group Skills DBT with no DBT individual sessions (DBT-S)
Description: DBT group skills training is 2.5 hours per week and includes individual case management.
Study: NCT04737876

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BX002-A
Description: bacteriophage cocktail
Study: NCT01676246

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 100 mg flupirtine intravenous
Description: Administration of 100 mg flupirtine intravenous (3 mg solution intravenously, 1 vial Kadadolon® inject)
Study: NCT04737876

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02474862

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prenatal Walking Program
Description: PWP is a gentle walking intervention tailored for pregnant women.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Postpartum Prep Program
Description: PPP participants will attend individually education sessions matched in number and duration to the sessions in PWP. PPP involves providing health information particularly relevant to expectant mothers, including both maternal and newborn well being.
Study: NCT01542138

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desonide
Description: Once-a-day applying on axillar hyperpigmentation for 9 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Niacinamide
Description: Once-a-day applying on axillar hyperpigmentation for 9 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Humectant placebo cream
Study: NCT02926963

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: samples collection : hair and skin biopsy
Study: NCT05778474

Intervention type: OTHER
Intervention: Healthy subjects
Description: Participants' ground spontaneous speed overground will be tested by means of the 10-meter walking test. Participants will be tested for their foot dominance by means of the Waterloo footedness questionnaire-revised. Participants will walk on a treadmill mounted on force sensors. The test sequence will be the following:~1. Familiarization. Participants will walk on the treadmill with the belt running at increasing velocities up to their spontaneous walking velocity . Speed will be increased of 0.2 m s-1 every 30 s. A brief pause of around 1 minute will follow.~2. Walking. Participants will walk at 0.4 m s-1 and 1.2 m s-1 for at least 30 seconds.~3. Walking with a rigid ankle-foot orthosis. Participants will walk at 0.4 m s-1 and 1.2 m s-1 for at least 30 seconds with an ankle-foot orthosis on the dominant lower limb.~Participants will repeat the last point (n°3) with the ankle-foot orthosis on the non-dominant lower limb. A 3-min pause will follow each section.

Intervention type: OTHER
Intervention: Pathologic group
Description: Participants will walk on a treadmill mounted on force sensors. They will walk freely, under tight supervision, but without hanging to any support. The test sequence will be the following:~4. Familiarization. Participants will walk on the treadmill with the belt running at increasing velocities up to their spontaneous walking velocity . Speed will be increased of 0.1 m s-1 every 30 s. A brief pause of around 1 minute will follow.~5. Walking. Participants will walk at 0.4 m s-1 for at least 30 seconds. Participants will be informed a few seconds before the changes in belts' velocities with a verbal warning.
Study: NCT03529253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab 75 MG/ML [Praluent]+ Rosuvastatin 10mg/daily
Description: Alirocumab group receive Alirocumab75mg/2week subcutaneous injection plus Rosuvastatin10mg/daily by oral for 9 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin calcium10mg
Description: Rosuvastatin10mg/daily by oral for 9 months.
Study: NCT02928796

Intervention type: BEHAVIORAL
Intervention: Cognitive Stimulus
Description: Participants to pay attention to a supplementary display monitor and respond to specified stimulus images, all while performing the simulated cardiology-based procedure.

Intervention type: BEHAVIORAL
Intervention: Cognitive Stimulus
Description: Participants to pay attention to a supplementary display monitor and respond to specified stimulus images, all while performing the simulated cardiology-based procedure.